Emergent BioSolutions Inc. (EBS)
EBS moved a median of -0.08% 30 minutes after news, and -0.46% by the close. How EBS actually reacts to news — the realized, point-in-time move the market made, measured across 458 labeled events over the last three years with zero look-ahead.
EBS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.09% | 51% | 454 |
| 30-min | -0.08% | 47% | 455 |
| 60-min | -0.07% | 48% | 455 |
| to close | -0.46% | 46% | 451 |
| Middle 50% of EBS reactions | -1.47% to +1.50% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 458 |
Half of all Emergent BioSolutions Inc. news events land between -1.47% and +1.50% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How EBS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | +0.30% | 54% | -0.66% |
| Rating reiterations | 40 | -0.47% | 25% | -0.49% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how EBS ranks against every other measured name →
That’s how EBS usually reacts — get an email when it moves on news →Email me when EBS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EBS's baseline. Nothing else.
Recent EBS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility | Press release | GlobeNewswire | -1.26% | +0.00% | |
| Form 8-K Emergent BioSolutions For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -1.26% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutions Inc. (EBS) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.16% | -0.24% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.00% | +1.96% | |
| Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes | Press release | GlobeNewswire | -0.15% | -5.03% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.00% | +0.55% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.25% | +3.49% | |
| Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) | Press release | GlobeNewswire | +1.22% | +0.97% | |
| Form 8-K Emergent BioSolutions For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | +2.73% | +3.69% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutions Inc. (EBS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.08% | +1.33% | |
| Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray | Press release | GlobeNewswire | -1.28% | +3.74% | |
| Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day | Press release | GlobeNewswire | -1.28% | +3.74% | |
| Emergent BioSolutions Inc. (EBS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.08% | -0.25% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutions Inc. (EBS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.17% | +2.23% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.46% | +3.68% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioSolutions Inc. (EBS) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.10% | +1.37% | |
| Emergent BioSolutions Inc. (EBS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +2.19% | +3.19% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.30% | +3.25% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutions Inc. (EBS) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.27% | +2.33% | |
| EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +0.05% | +0.84% | |
| Form 10-Q Emergent BioSolutions For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.22% | -7.65% | |
| Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment | Press release | GlobeNewswire | -1.22% | -7.65% | |
| Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -1.22% | -7.65% | |
| Form 8-K Emergent BioSolutions For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -1.22% | -7.65% | |
| Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026 | Press release | GlobeNewswire | +0.80% | +0.00% | |
| Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government | Press release | GlobeNewswire | -0.58% | -1.05% | |
| Form 8-K Emergent BioSolutions For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | +0.65% | |
| Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose | Press release | GlobeNewswire | +0.74% | +4.84% | |
| Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy | Press release | GlobeNewswire | +0.22% | -0.98% | |
| Emergent BioSolutions to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.06% | +0.74% | |
| Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] | Press release | GlobeNewswire | +2.78% | -1.69% | |
| Form 10-Q Emergent BioSolutions For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -11.48% | -2.48% | |
| Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox | Press release | GlobeNewswire | +0.50% | +2.11% | |
| Emergent BioSolutions Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -5.39% | -5.78% | |
| Form 8-K Emergent BioSolutions For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | +2.11% | |
| Form 8-K Emergent BioSolutions For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -5.39% | -5.78% | |
| Form S-8 Emergent BioSolutions | SEC filing · Form S-8 | SEC EDGAR | -5.39% | -5.78% | |
| Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives | Press release | GlobeNewswire | -1.51% | -2.08% | |
| Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 | Press release | GlobeNewswire | -1.51% | -2.08% | |
| Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States | Press release | GlobeNewswire | +0.00% | +1.60% | |
| Form DEFA14A Emergent BioSolutions | SEC filing · Form DEFA14A | SEC EDGAR | +0.12% | +1.11% | |
| Form DEFA14A Emergent BioSolutions | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +1.60% | |
| Form DEFA14A Emergent BioSolutions | SEC filing · Form DEFA14A | SEC EDGAR | -0.24% | -1.82% | |
| Form 8-K Emergent BioSolutions For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | -0.11% | -1.01% | |
| Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility | Press release | GlobeNewswire | -0.11% | -1.01% | |
| Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026 | Press release | GlobeNewswire | -0.11% | -1.01% | |
| Form DEFA14A Emergent BioSolutions | SEC filing · Form DEFA14A | SEC EDGAR | +0.35% | -0.46% | |
| Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program | Press release | GlobeNewswire | -1.67% | -5.24% | |
| Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness | Press release | GlobeNewswire | +0.26% | +0.64% | |
| Emergent BioSolutions Participates in Upcoming International Preparedness Conferences | Press release | GlobeNewswire | +0.12% | +0.12% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EBS section they belong to.
Where else EBS is measured.
EBS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Teleflex Incorporated (TFX) | 460 | -0.02% | 49% |
| CAS MEDICAL SYSTEMS (CASM) | 459 | 0.00% | 35% |
| REXAHN PHARMACEUTICALS (RNN) | 458 | -0.35% | 41% |
| NUVECTRA CORP COMMON (NVTR) | 456 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Emergent BioSolutions Inc.'s median reaction calculated?
Every labeled EBS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 458 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of EBS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EBS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.